Regulus Therapeutics, a biopharmaceutical company focused on developing drugs that target microRNA, filed on Friday with the SEC to raise up to $58 million in an initial public offering. The San Diego, CA-based company, which was formed in 2007 and booked $14 million in sales for the 12 months ended 6/30/2012, plans to list on the NASDAQ under the symbol RGLS. Lazard Capital Markets, Cowen & Company, and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
Regulus Therapeutics is backed by Isis Pharmaceuticals and Alnylam Pharmaceuticals, which currently own 45% and 44%, respectively. The company has entered into over 30 academic collaborations, most recently including agreements with AstraZeneca and Biogen Idec.
